Biovest International, Inc. (BVTI.OB), a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system, and a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), recently announced clinically and statistically significant unblinded data from the company’s randomized controlled pivotal Phase 3 fast-tracked clinical trial of BiovaxID®, a treatment for non-Hodgkin’s lymphoma.
BiovaxID® is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient’s own immune system to recognize and destroy cancerous B-cells that may remain in the body after chemotherapy treatment. BiovaxID® is designed to kill only cancerous B-cells for patients diagnosed with non-Hodgkin’s lymphoma, unlike other traditional medical treatments, such as radiation and chemotherapy, which destroy healthy cells and cancerous cells throughout the body. BiovaxID® could potentially be useful in the treatment of other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
Originally developed and advanced into human clinical trials by the National Cancer Institute (NCI), the Phase 3 trial for BiovaxID® supported highly encouraging clinical evidence on vaccinated patients regarding efficacy and safety. Biovest International intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the United States and in Europe.
Let us hear your thoughts below:
